Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 11, 2004, Pages 1553-1557

  Zahavi, A ^b   Geertzen, J H B ^a,b   Middel, B ^b   Staal, M ^b   Rietman, J S ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; DANTROLENE; SPASMOLYTIC AGENT; TIZANIDINE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BACTEREMIA; BRADYCARDIA; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG IMPLANT; DYSARTHRIA; EVALUATION; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HALLUCINATION; HEADACHE; HEALTH STATUS; HUMAN; HYPOTENSION; INFUSION PUMP; LONG TERM CARE; LONGITUDINAL STUDY; MALE; MENINGITIS; MENTAL DISEASE; MOBILIZATION; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; OUTCOMES RESEARCH; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY DISTRESS; SCORING SYSTEM; SEIZURE; SKIN DISEASE; SOMNOLENCE; SPASTICITY; SPINE INJURY; SYNCOPE; URINE INCONTINENCE; VISUAL DISORDER; VOMITING;

EID: 7244260312     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.014282     Document Type: Article

References (27)

1. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;ii:125-7.
2. Müller H, Zierski J, Dralle D. Pharmacokinetics of intrathecal baclofen. In: Müller H, Zierski J, Penn RD, eds. Local-spinal therapy of spasticity. Berlin: Springer Verlag, 1988:223-6.
3. Aisen ML, Dietz MA, Rossi P. Clinical and pharmacokinetic aspects of high dose oral baclofen therapy. J Am Paraplegia Soc 1992;15:211-16.
4. Azouvi P, Mane M, Thiebaut JB, et al. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil 1996;77:35-9.
5. Gianino JM, York MM, Paice JA, et al. Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs 1998;30:47-54.
6. Middel B, Kuipers-Upmeijer H, Bouma J, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997;63:204-9.
7. Coffey JR, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226-32.
8. Abel NA, Smith RA. Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehabil 1994;75:54-8.
9. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992;77:236-40.
10. Ordia JI, Fischer E, Adamski E, et al. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996;85:452-7.
11. Mertens P, Parise M, Garcia-Larrea L, et al. Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity. Acta Neurochir Suppl Wien 1995;64:17-25.
12. Patterson V, Watt M, Byrnes D, et al. Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. J Neurol Neurosurg Psychiatry 1994;57:582-5.
13. Gardner B, Jamous A, Teddy P, et al. Intrathecal baclofen: a multicentre clinical comparison of the Medtronics Programmable, Cordis Secor and Constant Infusion Infusaid drug delivery systems. Paraplegia 1995;33:551-4.
14. Penn RD. Intrathecal baclofen for severe spasticity. Ann NY Acad Sci 1988;531:157-66.
15. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-21.
16. Nance P, Schryvers O, Schmidt B, et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci 1995;22:22-9.
17. Saltuari L, Kronenberg M, Marosi MJ, et al. Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity. Acta Neurol Napol 1992;14:187-94.
18. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
20. La Rocca N. Field testing of a minimal record of disability in multiple sclerosis: the United States and Canada. Acta Neurol Scand 1984;70(suppl 101): 126-38.
21. Bergner M, Bobbit RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
22. Luteyn F, Hamel LF, Bouman TK. Hopkins symptom checklist (manual). Lisse: Swets and Zeitlinger, 1984.
23. Cohen J. Statistical power analysis for the behavioural sciences. New York: Academic Press, 1977.
24. Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987;66:181-5.
25. Parke B, Penn RD, Savoy SM, et al. Functional outcome of intrathecal baclofen. Arch Phys Med Rehabil 1989;70:30-2.
26. Meylhaler JM, Steers WD, Tuel SM, et al. Continuous intrathecal baclofen in spinal cord spasticity. A prospective study. Am J Phys Med Rehabil 1992;71:321-7.
27. Allbright AL, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebellar origin. J Neurosurg 2003;98:291-5.